We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-0.68%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.76B
AUM Growth
-$304M
Cap. Flow
+$23.1M
Cap. Flow %
0.49%
Top 10 Hldgs %
26.26%
Holding
167
New
11
Increased
69
Reduced
16
Closed
14

Top Buys

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$35.6M
2
WRBY icon
Warby Parker
WRBY
+$35M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$30.4M
4
IMRX icon
Immuneering
IMRX
+$29.3M
5
ABOS icon
Acumen Pharmaceuticals
ABOS
+$26.3M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$68.6M
2
ARDX icon
Ardelyx
ARDX
+$39.8M
3
BIIB icon
Biogen
BIIB
+$39.3M
4
BSX icon
Boston Scientific
BSX
+$34.2M
5
PPD
PPD, Inc. Common Stock
PPD
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.24%
2 Consumer Staples 1.58%
3 Industrials 0.82%
4 Financials 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADAP
101
DELISTED
Adaptimmune Therapeutics
ADAP
$11.3M 0.24%
2,189,788
+644,788
+42% +$2.89M
TRIL
102
DELISTED
Trillium Therapeutics Inc.
TRIL
$11M 0.23%
628,500
– –
OHPAU
103
DELISTED
Orion Acquisition Corp. Unit
OHPAU
$9.89M 0.21%
1,000,000
– –
INZY
104
DELISTED
Inozyme Pharma
INZY
$9.85M 0.21%
850,015
+9,743
+1% +$152K
SPRB
105
Spruce Biosciences
SPRB
$127M
$9.72M 0.2%
21,568
+168
+0.8% +$105K
FOLD
106
DELISTED
Amicus Therapeutics
FOLD
$9.67M 0.2%
1,012,506
– –
NRIX icon
107
Nurix Therapeutics
NRIX
$2.69B
$9.54M 0.2%
318,450
+3,100
+1% +$95.7K
DAWN
108
DELISTED
Day One Biopharmaceuticals
DAWN
$8.93M 0.19%
376,439
+2,700
+0.7% +$64.7K
XENE icon
109
Xenon Pharmaceuticals
XENE
$6.21B
$8.91M 0.19%
583,100
+10,600
+2% +$184K
KDNY
110
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$8.78M 0.18%
688,149
+5,700
+0.8% +$75K
OKUR
111
OnKure Therapeutics
OKUR
$164M
$8.52M 0.18%
114,319
+1,417
+1% +$120K
GMDA
112
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$8.42M 0.18%
2,147,400
+40,400
+2% +$202K
PRTK
113
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$8.09M 0.17%
1,665,014
+10,300
+0.6% +$56.8K
RYTM icon
114
Rhythm Pharmaceuticals
RYTM
$7.95B
$8M 0.17%
612,180
+5,900
+1% +$90.1K
FSTX
115
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$7.72M 0.16%
1,054,232
– –
KNTE
116
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$7.67M 0.16%
332,986
+1,400
+0.4% +$30.5K
CGEN icon
117
Compugen
CGEN
$221M
$7.66M 0.16%
1,283,790
+46,802
+4% +$313K
FUSN
118
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$7.51M 0.16%
948,327
– –
EAR
119
DELISTED
Eargo, Inc. Common Stock
EAR
$6.56M 0.14%
48,750
-23,750
-33% -$12.7M
FATE icon
120
Fate Therapeutics
FATE
$322M
$6.52M 0.14%
110,000
+40,000
+57% +$3.14M
STTK icon
121
Shattuck Labs
STTK
$682M
$6.39M 0.13%
313,499
– –
PHAS
122
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$5.73M 0.12%
1,843,764
– –
LONA
123
LeonaBio Inc
LONA
$70.5M
$5.18M 0.11%
55,225
-19,595
-26% -$1.99M
TBPH icon
124
Theravance Biopharma
TBPH
$876M
$5.09M 0.11%
687,500
– –
DSGN icon
125
Design Therapeutics
DSGN
$897M
$4.91M 0.1%
334,050
+2,000
+0.6% +$33.3K
3 4
5
6 7

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Rock Springs Capital Management held 167 positions worth $4.76B, down 6% from $5.06B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rock Springs Capital Management's Q3 2021 filing shows 11 new, 69 increased, 16 reduced and 14 closed positions. Its largest new stake was Baxter International: 450,000 shares worth $36.2M. The largest sale was BeOne Medicines Ltd, an estimated $68.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q3 2021 buy was Baxter International: 450,000 shares worth $36.2M.
  • Rock Springs Capital Management added most to Ultragenyx Pharmaceutical in Q3 2021, an estimated $30.4M increase.
  • Rock Springs Capital Management's biggest Q3 2021 reduction was Prothena Corp, cutting an estimated $14.9M.
  • Rock Springs Capital Management fully exited BeOne Medicines Ltd in Q3 2021, selling an estimated $68.6M.
  • Rock Springs Capital Management's ten largest holdings make up 26% of its $4.76B portfolio in Q3 2021.
  • Rock Springs Capital Management opened 11 new positions and closed 14 in Q3 2021.
  • Rock Springs Capital Management's portfolio value fell 6% quarter-over-quarter to $4.76B.

Based on Rock Springs Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.